Product image of Linagliptin/Metformin Hydrochloride Rowex (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Linagliptin/Metformin Hydrochloride Rowex

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Linagliptin/Metformin Hydrochloride Rowex (Metformin Hydrochloride, Linagliptin)

Linagliptin/Metformin Hydrochloride, the active ingredient in Linagliptin/Metformin Hydrochloride Rowex, is a DPP‑4 inhibitor; biguanide presented as an oral tablet for systemic use. It is indicated for the management of type 2 diabetes mellitus in adult patients, used as part of a comprehensive glycemic control plan.

GNH India supplies Linagliptin/Metformin Hydrochloride Rowex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards.

Manufacturer / TM Owner

Rowex Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin/Metformin Hydrochloride is used within the antidiabetic drug class to improve glycaemic control in type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (initial therapy): reduces fasting and post‑prandial glucose levels when combined with diet and exercise.
  • Type 2 diabetes mellitus (add‑on therapy): provides additional HbA1c reduction when metformin alone does not achieve target levels.
  • Type 2 diabetes mellitus (combination therapy): supports overall glycaemic management as part of a multi‑drug regimen alongside other antidiabetic agents.

How It Works

  • Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which raises endogenous incretin hormones (GLP‑1 and GIP) and enhances glucose‑dependent insulin secretion while suppressing glucagon release. Metformin hydrochloride decreases hepatic gluconeogenesis, improves peripheral insulin sensitivity, and increases glucose uptake in muscle, together lowering blood glucose concentrations.

Side Effects

Adverse reactions may occur with Linagliptin/Metformin Hydrochloride and are categorized by frequency.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal discomfort.
  • Diarrhoea: loose stools, often transient.
  • Abdominal discomfort: cramping or pain.
  • Headache: mild to moderate intensity.
  • Dizziness: occasional light‑headedness.
  • Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic complication.
  • Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Acute pancreatitis: sudden abdominal pain with elevated enzymes.
  • Renal impairment: worsening kidney function.
  • Allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatotoxicity: abnormal liver function tests.

Precautions & Warnings

When prescribing Linagliptin/Metformin Hydrochloride, clinicians should consider several safety aspects.

  • Renal function assessment: evaluate eGFR before initiation and periodically thereafter.
  • Lactic acidosis risk: avoid in patients with severe renal impairment or hepatic disease.
  • Hypoglycaemia monitoring: increase vigilance when used with insulin or sulfonylureas.
  • Pregnancy and lactation: prescribe only if potential benefits outweigh risks.
  • Drug‑interaction review: assess concomitant medications for possible interactions.
  • Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture.

Avoid Interactions

Linagliptin/Metformin Hydrochloride may interact with other medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: heightened risk of hypoglycaemia.
  • Iodinated contrast agents: may precipitate renal dysfunction with metformin.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): increase linagliptin exposure.

Moderate Interactions (Monitor Closely)

  • Diuretics: may affect renal clearance of metformin.
  • ACE inhibitors or ARBs: monitor renal function and potassium levels.
  • Beta‑blockers: can mask symptoms of hypoglycaemia.

Frequently Asked Questions

Linagliptin/Metformin Hydrochloride Rowex is an oral antidiabetic medication indicated for the treatment of type 2 diabetes mellitus in adults. It is used to improve glycaemic control when combined with diet and exercise, either as initial therapy or as an add‑on to other glucose‑lowering agents.

Linagliptin selectively blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which results in higher levels of the incretin hormones GLP‑1 and GIP. These hormones increase insulin secretion and reduce glucagon release in a glucose‑dependent manner, helping to lower blood sugar.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety in pregnancy and lactation has not been fully established. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin/Metformin combines a DPP‑4 inhibitor with a biguanide, offering complementary mechanisms: enhanced insulin secretion and reduced hepatic glucose production. Compared with sulfonylureas, it carries a lower risk of hypoglycaemia, and unlike some other DPP‑4 inhibitors, linagliptin does not require dose adjustment in renal impairment.

The product should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablets out of reach of children and do not use after the expiry date.

It is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis (particularly in patients with severe renal or hepatic impairment), severe hypoglycaemia when combined with insulin or sulfonylureas, and rare cases of acute pancreatitis. Patients should be educated to recognize symptoms and seek immediate medical attention if they occur.

Patients with known hypersensitivity to linagliptin, metformin, or any excipients should avoid the product. It is also contraindicated in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, and those with a history of lactic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT